“This systematic review and meta-analyses confirms that blood pressure lowering treatment is associated with reduced mortality and cardiovascular morbidity in people with diabetes mellitus, if systolic blood pressure before treatment is more than 140 mm Hg,” the authors wrote. “If SBP is less than 140 mm Hg, however, we found no benefit, but potential harm, with an increased risk of cardiovascular death.”
The authors concluded that the most likely biological explanation for the findings is the impairment of organ blood flow that can stem from intensive treatment. They suggest that blood pressure treatment goals should be less aggressive for patients with diabetes.
More articles on quality:
Researchers mine EHR data to identify patients with undiagnosed diabetes
A look at healthcare in Freddie Gray’s Baltimore: 5 major takeaways
5 animals capable of detecting infections and diseases in humans
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
